Abstract: Immunoglobulin Y (IgY) is a type of immunoglobulin found in birds and could be isolated from egg-yolk of chicken eggs. IgY is generally regarded as safe and offers various advantages in comparison to mammalian antibodies. IgY antibodies created to target specific antigens are intended to have a localized, highly target-specific, predictable, and efficient antigen-antibody interaction.Summary: IGY-110 is an IgY antibody that targets the spike proteins of the coronavirus, especially suitable for those most vulnerable from the infection (elderly and immunocompromised). IGY110 will be administered as a nasal spray. This novel approach allows the delivery of the antibodies directly to the nasal cavity, a key site of coronavirus entry and infection. IGY-110 is currently in preclinical trials and will begin clinical trials by early 2021.References: https://www.protheragen.com/available-projects/igy-antibody-against-covid-19/
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Antigen Products for Vaccine Development
CAR-T Cell-based Immunotherapy Basic Principles
What Are CAR-T Therapies
Practical Identifiability Analysis of QSP Models with LikelihoodProfiler
Ivan Borisov, Evgeny Metelkin
Stimulation of erythropoiesis with ESA or blood donation: QSP model
Alexander Stepanov, Galina Lebedeva